K. Adkison

发表

The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet

B. Wynne, R. Mehta, J. Piscitelli, 2020, Clinical pharmacology : advances and applications.

Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics.

Danny D Shen, Kimberly K Adkison, A. Artru, 2004, Advanced drug delivery reviews.

Pharmacokinetics and Short-Term Safety of 873140, a Novel CCR5 Antagonist, in Healthy Adult Subjects

S. Piscitelli, K. Adkison, Anne Shachoy-Clark, 2005, Antimicrobial Agents and Chemotherapy.

A Double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects

R. Hamatake, Z. Hong, M. Rodríguez-Torres, 2014, Liver international : official journal of the International Association for the Study of the Liver.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.

Rhys D O Jones, Vikash K. Sinha, V. Fischer, 2011, Journal of pharmaceutical sciences.

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

R. Davey, S. Piscitelli, K. Adkison, 2005, AIDS.

Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.

A. S. Gross, J. Polli, E. Lee, 2010, Journal of pharmaceutical sciences.

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ‐56914845 (GSK2336805) in subjects with hepatic impairment

William Smith, K. Adkison, T. Marbury, 2015, Journal of clinical pharmacology.

Use of "N-in-One" dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships.

K. Adkison, J. Berman, J. Shaffer, 1999, Journal of pharmaceutical sciences.

Synthesis and evaluation of potent and selective beta3 adrenergic receptor agonists containing heterobiaryl carboxylic acids.

K. Brown, C. Cowan, K. Adkison, 2007, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.

C. Cowan, K. Adkison, D. Uehling, 2002, Journal of medicinal chemistry.

Monitoring liver safety in drug development: the GSK experience.

C. Dollery, C. Hunt, T. Gibbs, 2007, Regulatory toxicology and pharmacology : RTP.

Steady-State Brain Concentrations of Antihistamines in Rats

Kelly H. Jordan, Larry J. Shampine, J. Polli, 2004, Pharmacology.

In Vitro and Clinical Investigation of the Relationship Between CCR5 Receptor Occupancy and Anti‐HIV Activity of Aplaviroc

S. Piscitelli, C. McDanal, K. Adkison, 2008, Journal of clinical pharmacology.

Effects of probenecid on brain-cerebrospinal fluid-blood distribution kinetics of E-Delta 2-valproic acid in rabbits.

A. Artru, D. Shen, K. Adkison, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacokinetics of Antiretroviral Drug Varies With Formulation in the Target Population of Children With HIV‐1

W. Snowden, D. Gibb, K. Adkison, 2012, Clinical pharmacology and therapeutics.

Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants

Rajendra Singh, B. Wynne, Allen Wolstenholme, 2021, Clinical pharmacology in drug development.

Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput.

K. Adkison, J Berman, K Halm, 1997, Journal of medicinal chemistry.

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection

R. Paredes, P. Cahn, L. Waters, 2019, AIDS research and human retroviruses.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.

Malcolm Rowland, Thierry Lavé, Rhys D O Jones, 2011, Journal of pharmaceutical sciences.

Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine

T. P. Dumitrescu, C. Spancake, Allen Wolstenholme, 2019, Clinical pharmacology in drug development.

Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open‐Label, Randomized Study

Allen Wolstenholme, K. Adkison, K. Hayward, 2017, Clinical pharmacology and therapeutics.

Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.

M. Danhof, O. Della Pasqua, K. Adkison, 2014, British journal of clinical pharmacology.

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection

B. Wynne, R. Mehta, Allen Wolstenholme, 2018, Antimicrobial Agents and Chemotherapy.

A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children.

M. Danhof, O. Della Pasqua, K. Adkison, 2014, British journal of clinical pharmacology.

Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children

W. Snowden, D. Gibb, K. Adkison, 2010, Journal of the International AIDS Society.

A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects

D. Wilfret, K. Adkison, A. Spaltenstein, 2014, Clinical pharmacology in drug development.

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial

A. Walker, P. Musoke, W. Snowden, 2010, Antiviral therapy.

Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs

Stephen A. Wring, Joseph W. Polli, Kimberly K. Adkison, 2002, Journal of Pharmacology and Experimental Therapeutics.

Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children

Allen Wolstenholme, K. Adkison, R. Parasrampuria, 2021, The Pediatric infectious disease journal.

Cassette dosing: rapid in vivo assessment of pharmacokinetics

P. Woollard, K. Wells-Knecht, K. Adkison, 1998 .

Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

D. Podzamczer, C. Orkin, Kimberly Smith, 2019, The lancet. HIV.

Role of choroid plexus epithelium in the removal of valproic acid from the central nervous system

A. Artru, D. Shen, K. Adkison, 1995, Epilepsy Research.

Distribution of Unsaturated Metabolites of Valproate in Human and Rat Brain‐Pharmacologic Relevance?

G. Ojemann, D. Shen, K. Adkison, 1995, Epilepsia.

Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail

S. Piscitelli, K. Adkison, B. Johnson, 2006, Journal of clinical pharmacology.

Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?

L. Shewchuk, A. Hassell, R. Gampe, 2006, Bioorganic & medicinal chemistry letters.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.

Thierry Lavé, Rhys D O Jones, James W T Yates, 2011, Journal of pharmaceutical sciences.

Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)

K. Kabeya, N. Clumeck, L. Curtis, 2007, Antimicrobial Agents and Chemotherapy.

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.

Malcolm Rowland, Thierry Lavé, Rhys D O Jones, 2011, Journal of pharmaceutical sciences.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.

Malcolm Rowland, Thierry Lavé, Volker Fischer, 2011, Journal of pharmaceutical sciences.

High-throughput screening for lead optimization: a rational approach.

M Bajpai, K K Adkison, K. Adkison, 2000, Current opinion in drug discovery & development.

Discovery of a Potent and Selective α1A Antagonist

D. Drewry, K. Adkison, J. Berman, 2002 .

Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.

K. Brown, C. Cowan, N. Cariello, 2006, Journal of medicinal chemistry.

Echocardiogram Study To Evaluate the Effect of the Novel Hepatitis C Virus NS5A Inhibitor GSK2336805 on Cardiac Contractility in Healthy Subjects

D. Wilfret, K. Adkison, W. Spreen, 2013, Antimicrobial Agents and Chemotherapy.

The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.

S. Piscitelli, K. Adkison, Anne Shachoy-Clark, 2006, British Journal of Clinical Pharmacology.

, of Aplaviroc ( GW 873140 ) Hepatotoxicity Observed in Clinical Trials

K. Kabeya, N. Clumeck, L. Curtis, 2008 .

Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults

D. Wilfret, K. Adkison, Lori S. Jones, 2014, Clinical pharmacology in drug development.

The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.

A. S. Gross, J. Polli, E. Lee, 2008, British journal of clinical pharmacology.

Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies

B. Wynne, R. Mehta, H. Crauwels, 2023, British journal of clinical pharmacology.

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136) *

A. Lazzarin, A. Lamarca, K. Adkison, 2009, HIV medicine.